Home / Market News / $ZYME

$ZYME news and market catalysts

The 20 most recent market catalysts affecting $ZYME, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

20 catalysts 6 high impact 16 bullish 1 bearish Biotechnology
Nov 16, 2026 Corporate Catalyst Bullish Impact 65
Zymeworks Announces $200 Million Share Repurchase Authorization
Zymeworks has authorized a new share repurchase program for up to $200 million, replacing a recently completed $125 million program. This action signals the company's commitment to…
Nov 9, 2026 Corporate Catalyst Bullish Impact 92
Zymeworks Reports Third Quarter 2026 Financial Results and Raises Full-Year Guidance
Zymeworks delivered a strong third quarter in 2026, beating analyst expectations for both revenue and EPS. This performance led to an upward revision of their full-year 2026 revenu…
Oct 24, 2026 Corporate Catalyst Bullish Impact 85
Zymeworks Presents Phase 1 Clinical Data for ZW191 at ESMO Congress 2026
Zymeworks announced positive Phase 1 clinical data for ZW191 in a difficult-to-treat patient population (platinum-resistant ovarian cancer), demonstrating a high objective response…
Oct 23, 2026 Corporate Catalyst Bullish Impact 92
Zymeworks Enters into Exclusive Global License and Collaboration Agreement with Roche for ZW209
Zymeworks has entered into an exclusive global license and collaboration agreement with Roche for ZW209, a trispecific T-cell engager. This is a major positive catalyst for Zymewor…
Oct 23, 2026 Corporate Catalyst Bullish Impact 85
Zymeworks and Roche Enter Exclusive Global License and Collaboration Agreement for ZW209
Zymeworks has secured a major partnership with Roche for its trispecific T-cell engager, ZW209. This agreement is highly positive for Zymeworks as it brings in a $55 million upfron…
Oct 7, 2026 Corporate Catalyst Bullish Impact 55
Truist Securities Maintains Buy on Zymeworks, Raises Price Target to $34
Truist Securities analyst Gregory Renza maintained a 'Buy' rating on Zymeworks and raised the price target from $32 to $34. This action indicates a positive outlook from a prominen…
Sep 29, 2026 Corporate Catalyst Bullish Impact 55
Citigroup Maintains Buy on Zymeworks, Raises Price Target to $39
Citigroup analyst Yigal Nochomovitz maintained a 'Buy' rating on Zymeworks and slightly increased the price target from $38 to $39. This action signals continued analyst confidence…
Sep 28, 2026 Corporate Catalyst Bullish Impact 85
Zymeworks Updates Annual Financial Targets After Finalizing Theravance Biopharma Deal
Zymeworks' 8-K filing details the finalization of its acquisition of Theravance Biopharma, a significant strategic move. The updated 2026 financial guidance, projecting $278M-$292M…
Sep 28, 2026 Corporate Catalyst Neutral Impact 75
Zymeworks Sees FY2026 Sales $278.000M-$292.000M vs $302.577M Est
Zymeworks announced its fiscal year 2026 sales guidance, projecting a range of $278 million to $292 million. This forecast is notably lower than the consensus analyst estimate of $…
Sep 28, 2026 Corporate Catalyst Neutral Impact 85
Zymeworks Guides FY26 Total Sales, Including Collaboration Revenue From YUPELRI, Of $278M-$292M And Adjusted EBITDA Of $114M-$128M
Zymeworks has completed its acquisition of Theravance Biopharma, a significant strategic move that immediately impacts its financial outlook. The company is now guiding for substan…
Sep 17, 2026 Corporate Catalyst Neutral Impact 55
Wolfe Research Initiates Coverage On Zymeworks with Outperform Rating
Wolfe Research analyst Kalpit Patel initiated coverage on Zymeworks with an 'Outperform' rating. This event signals a positive endorsement from a reputable research firm, suggestin…
Sep 3, 2026 Corporate Catalyst Bullish Impact 55
JP Morgan Maintains Overweight on Zymeworks, Raises Price Target to $33
JP Morgan analyst Brian Cheng maintained an 'Overweight' rating on Zymeworks and raised the price target from $31 to $33. This action signals a positive outlook from a prominent fi…
Aug 26, 2026 Corporate Catalyst Bullish Impact 55
Citigroup Maintains Buy on Zymeworks, Raises Price Target to $38
Citigroup analyst Yigal Nochomovitz has maintained a 'Buy' rating on Zymeworks and slightly increased the price target from $37 to $38. This action signals continued analyst confid…
Aug 26, 2026 Corporate Catalyst Bullish Impact 65
Zymeworks shares are trading higher after HC Wainwright & Co maintained its Buy rating on the stock and raised the price target from $51 to $55. Also, Citizens reiterated its Market Outperform rating and maintained a $32 price target.
This headline represents a positive corporate catalyst for Zymeworks. The maintained 'Buy' and 'Market Outperform' ratings, coupled with a price target increase from HC Wainwright …
Aug 26, 2026 Corporate Catalyst Bullish Impact 55
HC Wainwright & Co. Maintains Buy on Zymeworks, Raises Price Target to $55
HC Wainwright & Co. analyst Robert Burns has maintained a 'Buy' rating on Zymeworks and raised the price target from $51 to $55. This action signals continued analyst confidence in…
Aug 10, 2026 Corporate Catalyst Bullish Impact 55
B. Riley Securities Reiterates Buy on Zymeworks, Raises Price Target to $44
This 8-K filing discloses that B. Riley Securities analyst Mayank Mamtani has reaffirmed a 'Buy' rating on Zymeworks (ZYME) and raised the price target from $40 to $44. This is a p…
Aug 7, 2026 Corporate Catalyst Bullish Impact 55
Wells Fargo Maintains Overweight on Zymeworks, Raises Price Target to $40
Wells Fargo analyst Eva Fortea Verdejo maintained an 'Overweight' rating on Zymeworks and raised the price target from $37 to $40. This action signals continued confidence in the c…
Aug 7, 2026 Corporate Catalyst Bullish Impact 55
Truist Securities Maintains Buy on Zymeworks, Raises Price Target to $32
Truist Securities analyst Gregory Renza has maintained a 'Buy' rating on Zymeworks (ZYME) and slightly increased the price target from $31 to $32. This action signals continued ana…
Aug 6, 2026 Corporate Catalyst Bearish Impact 75
Zymeworks Q2 EPS $(0.62) Misses $(0.41) Estimate, Sales $4.590M Miss $18.011M Estimate
This headline represents a significant negative corporate catalyst for Zymeworks. The substantial miss on both EPS and sales estimates suggests that the company's financial perform…
Aug 5, 2026 Corporate Catalyst Bullish Impact 55
HC Wainwright & Co. Maintains Buy on Zymeworks, Raises Price Target to $51
HC Wainwright & Co. analyst Robert Burns maintained a 'Buy' rating on Zymeworks and raised the price target from $46 to $51. This action signals increased analyst confidence in Zym…
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.